https://ojs.bbwpublisher.com/index.php/CR <p><em>Cardiovascular Reviews</em>&nbsp;publishes peer-reviewed research articles across basic, translational, and clinical cardiovascular medicine. The journal aims to enhance insight into cardiovascular disease mechanisms and the prospects for innovation.&nbsp;The Journal covers all topics within cardiology and cardiovascular biology&nbsp;with an emphasis on studies that challenge the status quo of treatments,&nbsp;at the molecular, sub-cellular, cellular, organ, and organism level, and of clinical proof-of-concept and translational studies&nbsp;and practices in cardiovascular care or facilitate the translation of scientific advances into the clinic as new therapies or diagnostic tools.&nbsp;&nbsp;&nbsp;Manuscripts are expected to provide a significant contribution to the field with relevance for cardiovascular biology and diseases.</p> Bio-Byword Scientific Publishing PTY LTD en-US Cardiovascular Reviews 2981-8109 https://ojs.bbwpublisher.com/index.php/CR/article/view/9069 <p><em>Objective:</em> To analyze the clinical effect of percutaneous coronary intervention in the treatment of chronic coronary syndrome. <em>Methods:</em> 120 cases of chronic coronary syndrome patients who received inpatient treatment in a hospital from July 2023 to June 2024 were selected as the object, and were divided into the control group and the observation group using the mean score method, each with 60 cases, the control group was treated with conventional medications (aspirin, carbamazepine, β-receptor blockers, angiotensin-converting enzyme inhibitors, statin and other medications), and the observation group was treated with percutaneous The observation group implemented percutaneous coronary intervention based on this treatment, comparing the therapeutic effects of the two groups. <em>Results:</em> The treatment efficiency of the observation group (98.33%) was significantly higher than that of the control group (86.67%), and the difference was statistically significant (<em>P</em> &lt; 0.05); before treatment, the IVPWTd and LVEDd indexes of the patients in the control group and the observation group were (10.39 ± 0.86) mm, (55.36 ± 5.67) mm and (10.41 ± 0.78) mm, (56.01 ± 6.80) mm, respectively. The difference was not statistically significant (<em>P</em> &gt; 0.05); after 3 weeks of treatment, all the indexes of the two groups decreased significantly, respectively (9.76 ± 0.62) mm, (53.28 ± 5.63) mm and (8.56 ± 0.49) mm, (49.65 ± 5.47) mm, and the observation group was significantly lower than the control group, and the difference was statistically significant (<em>P</em> &lt; 0.05). In the control group, 3 cases of arrhythmia and 2 cases of coronary artery spasm occurred during the treatment period, and 1 case each of residual cardiac insufficiency, acute thrombosis, chronic renal impairment, and cardiogenic death, with a total incidence rate of 15%, while in the observation group, only 1 case of arrhythmia and 1 case of coronary artery spasm occurred, with a total incidence rate of 3.33%, and the difference between the groups was statistically significant (<em>P</em> &lt; 0.05). <em>Conclusion:</em> Percutaneous coronary intervention for the treatment of chronic coronary syndrome combined with renal disease is effective, can significantly improve the level of patients’ left ventricular function and reduces the risk of related complications, and is recommended to be popularized and applied in the clinic.</p> Yingxin Zhao Copyright (c) 2024 Author(s) 2024-12-10 2024-12-10 2 4 1 7 10.26689/cr.v2i4.9069 https://ojs.bbwpublisher.com/index.php/CR/article/view/8773 <p><em>Objective:</em> To analyze the clinical effect of percutaneous coronary intervention in the treatment of chronic coronary syndrome combined with kidney disease. <em>Methods:</em> 150 patients with chronic coronary syndrome combined with renal disease admitted to a hospital from June 2023 to May 2024 were selected, and were divided into the control group and the observation group, 75 cases each, using the mean score method. The control group implemented conventional drug (clopidogrel, aspirin, statins) treatment, and the observation group implemented percutaneous coronary intervention on this basis, comparing the two groups’ treatment effects. <em>Results:</em> The mortality rate (9.33%) and the deterioration rate of renal function (5.33%) of patients in the observation group during the treatment period were significantly lower than those of the control group (21.33%) and (16.00%). The average hospitalization time of patients in the observation group was shorter than that of the control group (15.75 ± 4.24) days. The recurrence rate of angina pectoris of the patients of the observation group in the three months after discharge from the hospital was lower than that of the control group (25.33%) and that of the observation group was lower than that of the control group (6.67%), the difference was statistically significant (<em>P</em> &lt; 0.05). Before treatment, there was no statistically significant difference in the levels of LVEDD, LVESD, and LVEF between the two groups (<em>P</em> &gt; 0.05). After three months of treatment, the LVEDD (52.55 ± 4.02) mm and LVESD (41.44 ± 2.17) mm in the patients of the observation group were lower than those of the control group (57.37 ± 3.74) mm and (46.44 ± 2.59) mm; LVEF (50.78 ± 5.97)% of patients in the observation group was higher than that of (43.06 ± 5.92)% in the control group, and the difference was statistically significant (<em>P</em> &lt; 0.05). Before treatment, there was no statistically significant difference in the levels of CK-MB and cTnI between the two groups (<em>P</em> &gt; 0.05). At 24h and 72h after treatment, the levels of CK-MB and cTnI in patients of the observation group and the control group were (35.21 ± 9.81) U/L, (1.24 ± 0.34) μg/L, (13.19 ± 5.12) U/L, (0.36 ± 0.08) μg/L and (38.79 ± 10.84) U/L, (1.45 ± 0.32) μg/L, (19.87 ± 4.76) μg/L, (0.58 ± 0.11) μg/L, the difference was statistically significant (<em>P</em> &lt; 0.05). <em>Conclusion:</em> Percutaneous coronary intervention is effective in treating chronic coronary syndrome combined with renal disease, which can significantly improve the level of a patient’s cardiac function and reduce the level of CK-MB and cTnI, and is worth being widely used in clinical practice.</p> Yingxin Zhao Copyright (c) 2024 Author(s) 2024-12-10 2024-12-10 2 4 8 14 10.26689/cr.v2i4.8773